In the present study, we examined the dynamic responses of lung cancer cells to KRASG12C inhibitors and found that multiple receptor tyrosine kinases (RTKs), including ERBB2, ERBB3, and FGFR1, may contribute to drug tolerance and resistance. This evidence concerns the gene FGFR1 and lung carcinoma.